ATP-Based Chemotherapy Response Assay in Patients with Unresectable Gastric Cancer

Park, Jeong Youp; Kim, Yong Soo; Bang, Seungmin; Hyung, Woo Jin; Noh, Sung Hoon; Choi, Sung Ho; Song, Si Young

doi:10.1159/000136802

Cited by 12 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although they suggested potential benefits of ATP-CRA guided chemotherapy by demonstrating complete remission and long-term survival, they could not evaluate the methodological stability of ATP-CRA. (29) The other is a study similar to our study. However, Lee(30) showed only cell death rate at a specific concentration of chemotherapeutic agent.…”

Section: Discussionsupporting

confidence: 66%

See 1 more Smart Citation

In VitroAdenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer

et al. 2010

Self Cite

View full text Add to dashboard Cite

PurposeThe purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer.Materials and MethodsA total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index.ResultsThe failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin.ConclusionsATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.

show abstract

Section: Discussionsupporting

confidence: 66%

“…(29,30) One is a study of the effectiveness of ATP-CRA guided chemotherapy for unresectable gastric cancer patients. Although they suggested potential benefits of ATP-CRA guided chemotherapy by demonstrating complete remission and long-term survival, they could not evaluate the methodological stability of ATP-CRA.…”

Section: Discussionmentioning

confidence: 99%

In VitroAdenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…Proliferation was reduced and apoptosis induced in the human gastric carcinoma cell line (HGC-27) by ATP and adenosine [593,692]. The benefits of chemotherapeutic drugs in patients with gastric cancer have been examined using an ATP-based chemotherapy response assay [426,540]. Infection of the gastric body by Heliobacter pylori contributes to the progression of gastric carcinoma [592].…”

Section: Injurymentioning

confidence: 99%

Purinergic signalling in the gastrointestinal tract and related organs in health and disease

Burnstock

2013

Purinergic Signalling

View full text Add to dashboard Cite

Purinergic signalling plays major roles in the physiology and pathophysiology of digestive organs. Adenosine 5′-triphosphate (ATP), together with nitric oxide and vasoactive intestinal peptide, is a cotransmitter in nonadrenergic, non-cholinergic inhibitory neuromuscular transmission. P2X and P2Y receptors are widely expressed in myenteric and submucous enteric plexuses and participate in sympathetic transmission and neuromodulation involved in enteric reflex activities, as well as influencing gastric and intestinal epithelial secretion and vascular activities. Involvement of purinergic signalling has been identified in a variety of diseases, including inflammatory bowel disease, ischaemia, diabetes and cancer. Purinergic mechanosensory transduction forms the basis of enteric nociception, where ATP released from mucosal epithelial cells by distension activates nociceptive subepithelial primary afferent sensory fibres expressing P2X3 receptors to send messages to the pain centres in the central nervous system via interneurons in the spinal cord. Purinergic signalling is also involved in salivary gland and bile duct secretion.

show abstract

“…Recently, an ATP-CRA test was shown to be useful in lung and breast cancer treatment [25,26]. Neoadjuvant chemotherapy potentially benefits individualized chemotherapy based on an individualized tumor response test, as evidenced by cases of complete response and long-term survival in patients with unresectable gastric cancer [27].…”

Section: Discussionmentioning

confidence: 99%

Metastatic Lymph Node Targeted Chemosensitivity Test for Gastric Cancer

Jang¹,

Kim²,

Park³

et al. 2011

Journal of Surgical Research

View full text Add to dashboard Cite

ATP-Based Chemotherapy Response Assay in Patients with Unresectable Gastric Cancer

Cited by 12 publications

References 8 publications

In VitroAdenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer

In VitroAdenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer

Purinergic signalling in the gastrointestinal tract and related organs in health and disease

Metastatic Lymph Node Targeted Chemosensitivity Test for Gastric Cancer

Contact Info

Product

Resources

About